TY - JOUR
T1 - Cohort profile
T2 - rationale and methods of UK Biobank repeat imaging study eye measures to study dementia
AU - UK Biobank and UK Biobank Eye and Vision Consortium
AU - Foster, Paul J
AU - Atan, Denize
AU - Khawaja, Anthony
AU - Lotery, Andrew
AU - MacGillivray, Tom
AU - Owen, Christopher G
AU - Patel, Praveen J
AU - Petzold, Axel
AU - Rudnicka, Alicja
AU - Sun, Zihan
AU - Sheard, Simon
AU - Allen, Naomi
N1 - Funding Information:
The study sponsor/funder was not involved in the design of the study; the collection, analysis and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report. UK Biobank is funded by the Medical Research Council, Wellcome Trust, Department of Health, Scottish Government, the Welsh Assembly Government, British Heart Foundation, Cancer Research UK, NIHR and the Northwest Regional Development Agency. The UK Biobank Eye and Vision Consortium is supported by grants from Moorfields Eye Charity, the NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, the Alcon Research Institute and the International Glaucoma Association (UK). AK, AP, ZS, PJF and PJP receive salary support from the NIHR BRC at Moorfields Eye Hospital & UCL Institute of Ophthalmology. NA receives salary support from University of Oxford and UK Biobank. PJF receives support from the Desmond Foundation, London, UK. AK is supported by a UKRI Future Leaders Fellowship and an Alcon Research Institute Young Investigator Award. TM acknowledges support from NHS Lothian R&D and the Clinical Research Facility at the University of Edinburgh. The authors acknowledge a proportion of our financial support from the UK Department of Health through an award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Biomedical Research Centre for Ophthalmology.
Funding Information:
PJF reports personal fees from Allergan, Carl Zeiss, Google/DeepMind and Santen, a grant from Alcon, outside the submitted work. PJP reports grants from Topcon Inc, outside the scope of the current report. AK reports personal fees from Abbvie, Aerie, Google Health, Novartis, Reichert, Santen and Thea, outside the submitted work. AP reports grant support for remyelination trials in multiple sclerosis to the Amsterdam University Medicam Centre, Department of Neurology, MS Centre (RESTORE trial) and UCL, London RECOVER trial; Fight for Sight (nimodipine in optic neuritis trial); royalties or licenses from Up-to-Date (Wolters Kluver) on a book chapter; speaker fees for the Heidelberg Academy; participation on Advisory Board SC Zeiss OCTA Angi-Network, SC Novartis OCTiMS study; equipment: OCTA from Zeiss (Plex Elite).
Funding Information:
The study sponsor/funder was not involved in the design of the study; the collection, analysis and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report. UK Biobank is funded by the Medical Research Council, Wellcome Trust, Department of Health, Scottish Government, the Welsh Assembly Government, British Heart Foundation, Cancer Research UK, NIHR and the Northwest Regional Development Agency. The UK Biobank Eye and Vision Consortium is supported by grants from Moorfields Eye Charity, the NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, the Alcon Research Institute and the International Glaucoma Association (UK). AK, AP, ZS, PJF and PJP receive salary support from the NIHR BRC at Moorfields Eye Hospital & UCL Institute of Ophthalmology. NA receives salary support from University of Oxford and UK Biobank. PJF receives support from the Desmond Foundation, London, UK. AK is supported by a UKRI Future Leaders Fellowship and an Alcon Research Institute Young Investigator Award. TM acknowledges support from NHS Lothian R&D and the Clinical Research Facility at the University of Edinburgh. The authors acknowledge a proportion of our financial support from the UK Department of Health through an award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Biomedical Research Centre for Ophthalmology.
Publisher Copyright:
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
PY - 2023/6/23
Y1 - 2023/6/23
N2 - PURPOSE: The retina provides biomarkers of neuronal and vascular health that offer promising insights into cognitive ageing, mild cognitive impairment and dementia. This article described the rationale and methodology of eye and vision assessments with the aim of supporting the study of dementia in the UK Biobank Repeat Imaging study.PARTICIPANTS: UK Biobank is a large-scale, multicentre, prospective cohort containing in-depth genetic, lifestyle, environmental and health information from half a million participants aged 40-69 enrolled in 2006-2010 across the UK. A subset (up to 60 000 participants) of the cohort will be invited to the UK Biobank Repeat Imaging Study to collect repeated brain, cardiac and abdominal MRI scans, whole-body dual-energy X-ray absorptiometry, carotid ultrasound, as well as retinal optical coherence tomography (OCT) and colour fundus photographs.FINDINGS TO DATE: UK Biobank has helped make significant advances in understanding risk factors for many common diseases, including for dementia and cognitive decline. Ophthalmic genetic and epidemiology studies have also benefited from the unparalleled combination of very large numbers of participants, deep phenotyping and longitudinal follow-up of the cohort, with comprehensive health data linkage to disease outcomes. In addition, we have used UK Biobank data to describe the relationship between retinal structures, cognitive function and brain MRI-derived phenotypes.FUTURE PLANS: The collection of eye-related data (eg, OCT), as part of the UK Biobank Repeat Imaging study, will take place in 2022-2028. The depth and breadth and longitudinal nature of this dataset, coupled with its open-access policy, will create a major new resource for dementia diagnostic discovery and to better understand its association with comorbid diseases. In addition, the broad and diverse data available in this study will support research into ophthalmic diseases and various other health outcomes beyond dementia.
AB - PURPOSE: The retina provides biomarkers of neuronal and vascular health that offer promising insights into cognitive ageing, mild cognitive impairment and dementia. This article described the rationale and methodology of eye and vision assessments with the aim of supporting the study of dementia in the UK Biobank Repeat Imaging study.PARTICIPANTS: UK Biobank is a large-scale, multicentre, prospective cohort containing in-depth genetic, lifestyle, environmental and health information from half a million participants aged 40-69 enrolled in 2006-2010 across the UK. A subset (up to 60 000 participants) of the cohort will be invited to the UK Biobank Repeat Imaging Study to collect repeated brain, cardiac and abdominal MRI scans, whole-body dual-energy X-ray absorptiometry, carotid ultrasound, as well as retinal optical coherence tomography (OCT) and colour fundus photographs.FINDINGS TO DATE: UK Biobank has helped make significant advances in understanding risk factors for many common diseases, including for dementia and cognitive decline. Ophthalmic genetic and epidemiology studies have also benefited from the unparalleled combination of very large numbers of participants, deep phenotyping and longitudinal follow-up of the cohort, with comprehensive health data linkage to disease outcomes. In addition, we have used UK Biobank data to describe the relationship between retinal structures, cognitive function and brain MRI-derived phenotypes.FUTURE PLANS: The collection of eye-related data (eg, OCT), as part of the UK Biobank Repeat Imaging study, will take place in 2022-2028. The depth and breadth and longitudinal nature of this dataset, coupled with its open-access policy, will create a major new resource for dementia diagnostic discovery and to better understand its association with comorbid diseases. In addition, the broad and diverse data available in this study will support research into ophthalmic diseases and various other health outcomes beyond dementia.
KW - Humans
KW - Prospective Studies
KW - Biological Specimen Banks
KW - Retina/diagnostic imaging
KW - Eye Diseases
KW - Dementia/diagnostic imaging
KW - United Kingdom/epidemiology
U2 - 10.1136/bmjopen-2022-069258
DO - 10.1136/bmjopen-2022-069258
M3 - Article
C2 - 37355273
SN - 2044-6055
VL - 13
JO - BMJ Open
JF - BMJ Open
IS - 6
M1 - e069258
ER -